Fig 1: Validation of proteomic prognostic biomarkers using enzyme-linked immunosorbent assay (ELISA). The serum level of LTA4H in allergen immunotherapy (AIT) non-responders (A) and AIT responders (B). (C) Receiver-operator characteristic (ROC) curve of LTA4H measured using ELISA. The serum level of MUC5B in AIT non-responders (D) and responders (E). The serum level of lipopolysaccharide binding protein (LBP) in AIT non-responders (F) and responders (G). The serum level of C4BPB in AIT non-responders (H) and responders (I).
Fig 2: Expression level of potential biomarkers (MUC5B, LBP, C4BPB and LTA4H) of allergen immunotherapy (AIT) efficacy identified by MS-based proteomics in AIT responder cohort.
Supplier Page from CUSABIO Technology LLC for Human C4b-binding protein beta chain(C4BPB) ELISA Kit